Alzheimer's Disease Trial, Not Yet Recruiting NCT07505095 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Not Yet Recruiting

NCT07505095
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with mild cognitive impairment (MCI) or early Alzheimer's disease, confirmed by a specific brain scan showing signs of Alzheimer's-related changes in the brain.
  • People of any gender (male or female).
  • People aged between 50 and 85 years old.
  • People who are not currently taking part in any other research studies.
  • People who are willing and able to give written consent to participate in the study before it begins.
  • People who are able to communicate clearly with the research team and follow the study procedures through to completion.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have another type of neurological (brain or nervous system) condition, such as vascular dementia, Lewy body dementia, frontotemporal dementia, or prion diseases.
  • People who have certain whole-body illnesses or conditions affecting the body's chemical processes, such as an underactive thyroid, vitamin B12 deficiency, or liver or kidney failure.
  • People who have certain infections affecting the brain or nervous system, such as neurosyphilis, HIV-related brain disease, or other similar infections.
  • People whose memory or thinking problems are caused by a psychiatric condition, such as severe depression or schizophrenia.
  • People who have long-term use of certain medications (such as benzodiazepines or anticholinergic drugs) or who have alcohol dependence, where these may be affecting brain function.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 29 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 13958125492

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
30 April 2026
Est. completion
30 April 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Aβ-PET centiloid values

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov